Synlogic Inc · OTC:SYBX
Synlogic — Corporate Update (September 2021)
29 slides from Synlogic's corporate update, Sep 20, 2021
Slide 1: Designed for Life: Phenylketonuria Clinical Program Update
Designed for Life Phenylketonuria Clinical Program Update 20 September 2021 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: Our Program Today
Our Program Today Interim Analysis of SYNB1618 Phase 2 SynPheny-1 Study Dr. Aoife Brennan, CEO 01 SYNB1934 Phase I Data, Dose Cohorts 1-3 Dr. David Hava, CSO 02 Platform Implications and Next Steps in PKU Dr. Aoife Brennan, CEO 03 Q&A Management Team 04
Slide 4: Progress in Phenylketonuria
Progress in Phenylketonuria Dr. Aoife Brennan, MB CHB President & CEO
Slide 5: Synthetic Biotic Medicines: a novel approach in Phenylketonuria (PKU)
Synthetic Biotic Medicines: a novel approach in Phenylketonuria (PKU) Potential to treat all PKU patients with a safe oral approach Synthetic Biotic Medicines Today: two trials with interim results Current and emerging treatment options leave many patients behind PKU SYNB1618 strain achieved prespec
Slide 6: PKU remains an area of high unmet need
PKU remains an area of high unmet need Adults ~12,300 U.S. 65% out of Phe control Pediatrics ~5,000 U.S. 25% out of Phe control Patients Julia, living with PKU 90% of patients and caregivers express need for greater natural protein intake (1) (1) Puurunen et al, Global PKU Patient Meeting, September
Slide 7: PKU patients are poorly served today
Disease State Out of Phe Control (>360 μmol/L of Phe) In Phe control (<360 μmol/L of Phe) Patient Goal Lower blood Phe to reduce risk of neurocognitive impairment Enable greater dietary protein intake while maintaining Phe control PKU patients are poorly served today Significant market opportunity,
Slide 8: Differentiated product candidates for the treatment of PKU
Synthetic Biotic Medicines: Differentiated product candidates for the treatment of PKU Synthetic Biotic medicines for the treatment of PKU present a compelling opportunity to change patients’ lives Designed for PKU Oral Reversible Gut Restricted
Slide 9: Intuitive and direct approach to treating PKU
Intuitive and direct approach to treating PKU Unique mechanism of action generates quantitative, measurable biomarker of Phe metabolism: TCA (trans-cinnamic acid) Oral therapy, 3 x day with meals Dietary Phe Reduce plasma Phe or enhance protein tolerance Converted by Synthetic Biotic to harmless met
Slide 10: Interim Analysis of SYNB1618 SynPheny-1 Phase 2 Study in PKU
Interim Analysis of SYNB1618 SynPheny-1 Phase 2 Study in PKU
Slide 11: SYNB1618 Phase 2 SynPheny-1 study in PKU: Design
6-day diet run in Individualized diet plan to match baseline Phe intake Stable study diet: diet run-in through 2 weeks post treatment Diet Control Endpoints Fasting Plasma Phe levels (day -1, 7, 14, 29) Labelled D5-Phe 24hr AUC, change from baseline after meal challenge (day -1, 15) Day 29 Fasting P
Slide 12: SYNB1618 metabolized Phe into TCA and prevented Phe absorption after meal challenge
SYNB1618 metabolized Phe into TCA and prevented Phe absorption after meal challenge Percent change from baseline +/- 95% confidence interval. TCA = trans-cinnamic acid. AUC = Area under curve. 4 of 8 patients experienced >40% D5-Phe lowering after meal challenge TCA Production Phe absorption into pl
Slide 13: SYNB1618 reduced fasting plasma Phe levels
SYNB1618 reduced fasting plasma Phe levels Fasting Plasma Phe Levels (N=8) Percent change from baseline +/- 95% confidence interval. * = Statistically significant Cessation of treatment 4 of 8 patients experienced >30% reduction in fasting Plasma Phe at Day 7 or Day 14
Slide 14: Summary of interim safety analysis
Summary of interim safety analysis Safety analysis cut-off: 30 July 2021. Includes all patients (N = 9) through Day 15. Does not include Day 29 assessments for all patients. One discontinuation for anxiety, not drug related. Gut restricted Clearance upon cessation of dosing as expected Generally wel
Slide 15: SYNB1934 Phase 1 Study Results
SYNB1934 Phase 1 Study Results Dr. David Hava, PhD Chief Scientific Officer
Slide 16: Synthetic biology platform optimized activity of therapeutic strain
Synthetic biology platform optimized activity of therapeutic strain Increased activity in vivo (Non-human primates) Monahan et al, SEED 2021. * = Statistically significant. Error bar is mean +/- standard deviation. * SYNB1934 Developed from SYNB1618 using directed evolution of PAL3 enzyme in whole c
Slide 17: SYNB1934 Ph. 1 study allows head-to-head comparison of strains
SYNB1934 Ph. 1 study allows head-to-head comparison of strains 3x1011 SYNB1934 1x1012 SYNB1934 Optional higher SYNB1934 Cohort 2 Cohort 1 Cohort 3 Cohort 4 Study Design Endpoints Safety and tolerability Biomarkers of Phe consumption SYNB1934 clearance after cessation of dosing 6x1011 SYNB1934 6x1011
Slide 18: SYNB1934 Dose Response (D5-TCA)
Mean +/- 90% confidence interval. TCA = trans-cinnamic acid SYNB1934 Dose Response (D5-TCA) SYNB1934 metabolized labeled D5-Phe in a dose dependent manner N = 32 SYNB1934 exhibited clear and consistent dose responsive activity in humans
Slide 19: SYNB1934 demonstrated two-fold improvement over SYNB1618
Mean +/- 90% confidence interval. TCA = trans-cinnamic acid HA = hippuric acid SYNB1934 demonstrated two-fold improvement over SYNB1618 in biomarkers of Phe metabolism SYNB1934 and SYNB1618 D5-TCA and D5-HA N = 12
Slide 20: Robust labeled D5-Phe reduction in healthy volunteers at multiple dose levels
Robust labeled D5-Phe reduction in healthy volunteers at multiple dose levels Percent change from baseline +/- 90% confidence interval. Cross study comparison. N = total study (all cohorts) D5 Phe Reduction: SYNB1618 Previously Presented D5 Phe Reduction: SYNB1934 Current Study N = 32 N = 88
Slide 21: Prospective modeling for SYNB1618 predicted clinical activity
Prospective modeling for SYNB1618 predicted clinical activity Model range represents relative activity of enzymes: PAL and LAAD Prospective biomarker driven modeling suggests SYNB1934 provides opportunity for increased Phe lowering Prospective Model Results (1e12 Live Cells) SYNB1618 Modeling Model
Slide 22: Expectation of improved clinical profile
Healthy volunteers PKU Patients SYNB1618 1e12 dose SYNB1934 1e12 dose 7% D5-Phe reduction post-meal 27% D5-Phe reduction post-meal 20% Fasting plasma Phe Expectation of improved clinical profile SYNB1934 to be evaluated in new arm of SynPheny-1 study
Slide 23: Portfolio Implications and Next Steps in PKU
Portfolio Implications and Next Steps in PKU
Slide 24: Synthetic Biotic Platform is enabling engine for drug development
Synthetic Biotic Platform is enabling engine for drug development Internal process development and GMP manufacturing of live biotherapeutic Modular SynBio components enables rapid, iterative product development Prospective, biomarker driven modeling predictive of therapeutic effect Deep synthetic bi
Slide 25: Synthetic Biotic platform enables portfolio of high value metabolic indications
SYNB1618 Synthetic Biotic platform enables portfolio of high value metabolic indications Exploratory Preclinical IND-Enabling Studies Phase 1 Phase 2 Phenylketonuria (PKU) SYNB1618 SYNB1934 IA Data: Today Head-to-Head Data: Today Phase 2 Data: H1 2022 Enteric Hyperoxaluria SYNB8802 Phase 1B Data: 20
Slide 26: PKU program to rapidly advance towards pivotal program
PKU program to rapidly advance towards pivotal program H2 2021 H2 2022 H1 2022 Demonstrated proof of concept of SYNB1618 DELIVERED Ph. 2 SynPheny Interim Analysis Head-to-head data in HV (SYNB1618 & SYNB1934 strain) DELIVERED Ph2 SynPheny full read-out (SYNB1618 & SYNB1934 strain) EXPECTED Start of
Slide 27: Synthetic Biotic Medicines: a novel approach in Phenylketonuria (PKU)
Synthetic Biotic Medicines: a novel approach in Phenylketonuria (PKU) SYNB1618 strain achieved prespecified 20% Phe lowering target in PKU patients SYNB1934 strain demonstrated two-fold greater activity than SYNB1618 in healthy volunteers SYNB1934 Ph. 1 HV Synlogic intends to begin pivotal study pla
Slide 28: Thank you to our study sites, patients, and investigators
Thank you to our study sites, patients, and investigators
Slide 29: Available For Questions
Available For Questions Dave Hava, PhD Chief Scientific Officer Daniel Rosan Head of Finance & Investor Relations Aoife Brennan, MB ChB President & CEO Antoine Awad Chief Operating Officer